Submission Deadline 01/07/2027
Fiscal Capacity $50,135,013
| Opportunity Number | PAR-25-026 |
|---|---|
| Agency | HHS-NIH11 |
| Application Deadline | 01/07/2027 |
| Award Amount | $50,135,013 |
| Status | Posted |
| Sector | Health |
| Cost Sharing | Not Required |
Fiscal Parameters & Taxonomy
Authority HHS-NIH11
Status Posted
Who Can Apply
Private institutions of higher education State governments Native American tribal governments (Federally recognized) City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Independent school districts Small businesses
Eligibility Intelligence
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Program Description
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
CFDA Programs
93.233 National Center on Sleep Disorders Research
93.837 Cardiovascular Diseases Research
93.838 Lung Diseases Research
93.839 Blood Diseases and Resources Research
93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Agency Contact
Related Intelligence Guides
In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.